Objectives: To examine rates of smoking and tobacco treatment utilization by insurance coverage status (Medicaid, commercial, exchange) among newly enrolled patients in the post Affordable Care Act (ACA) era.
S
moking remains the leading cause of preventable mortality in the United States. 1 In California, nearly 4 million people smoke, resulting in over $18 billion annually in direct health care costs and indirect costs due to smoking-related premature death, illness, and lost productivity. 2 Although most smokers want to quit smoking, 3 effective tobacco treatments are underused due to a variety of barriers. These challenges apply particularly to medically underserved and low-income populations, who typically smoke at disproportionately high rates, lack access to appropriate treatment, and cannot afford cessation medications. 3 The 2010 Patient Protection and Affordable Care Act (ACA), 4 had major implications for increasing access to tobacco treatment, by expanding benefits for underserved and low-income smokers. Specifically, the ACA-mandated comprehensive coverage for tobacco treatment, including counseling and US Food and Drug Administration (FDA)-approved medications, 5 was implemented for most private health plans and newly eligible Medicaid beneficiaries in California. ACA implementation in California in January 2014, [5] [6] [7] [8] including Medicaid expansion, exchange coverage, and comprehensive coverage for tobacco treatments without cost-sharing or prior authorization, has been associated with the reduction in uninsured population from 22% to 11% 6 and with bringing high-priority populations for tobacco control into the health care system, 6,9 including the 1.4 million individuals who gained private insurance through the California insurance exchange and 2.4 million who enrolled in Medicaid in 2014. 6, 8 Populations with the greatest gains in health care coverage through the ACA in California were adults aged 19-34, men, and low-income enrollees 6 the same subgroups disproportionately represented among California's smokers. 3, 10, 11 The ACA has the potential to increase access to tobacco treatment for previously medically underserved subgroups of smokers with possible pent-up demand for such services. For example, previous studies have demonstrated that Medicaid recipients, while more likely to smoke, are less likely to use tobacco treatment. [12] [13] [14] However, it is not clear whether expansion of coverage is sufficient to improve utilization of these services. In particular, Medicaid recipients and other vulnerable subgroups may face unique barriers to tobacco treatment use not related to coverage, such as difficulty navigating the health care system, lack of knowledge of benefits, 15 or competing medical and psychiatric health care needs.
In this study, we examine risk factors for smoking among newly enrolled patients following ACA implementation and the role of insurance status (ie, Medicaid, exchange, commercial coverage) as a predictor of tobacco treatment use (medication, counseling) among smokers post-ACA. To our knowledge, the current study is one of the first to use an extensive electronic health record (EHR) with population-based smoking screening to characterize smokers post-ACA in a multispecialty health care system.
METHODS

Setting
Kaiser Permanente Northern California (KPNC) is a nonprofit, multispecialty health care delivery system providing comprehensive health services to >3.9 million members 16 and covering >40% of the region's commercially insured population. 17 KPNC has 24 hospitals, 47 medical centers, and >7000 physicians who practice exclusively with KPNC. KPNC provides integrated medical and behavioral health treatment and is a recognized leader in establishing tobacco quality of care standards. 18 The membership is racially and socioeconomically diverse, and highly representative of the population from its geographic area. 19 The study protocol was approved by the KPNC Institutional Review Board.
Study Sample
The sample included 122,298 patients aged 18 and older who were newly enrolled in KPNC in the first 6 months of 2014 through Medicaid (including Medicaid expansion), the California exchange, or commercial plans purchased by small or large employers or by individuals outside of the exchange. Because we anticipated that differences in utilization by coverage type (eg, due to differences in pent-up demand) would be greatest in the early post-enrollment period, we limited sample enrollment to the first 6 months of 2014. Patients who had been enrolled in KPNC the prior 6 months, and those with Medicare coverage, unknown coverage, missing birth date, missing smoking status, enrollment for <60% of the first 6 membership months and enrollment gaps of >45 days in the first 6 months of membership were excluded. Exclusion criteria were derived from the EHR. Of the 122,298 eligible patients, 15,936 were documented in the EHR as current smokers during the first 6 months of enrollment. Among these, 1720 enrolled through Medicaid plans, 4512 enrolled through the California exchange, and 9704 through commercial plans (Appendix 1, Supplemental Digital Content 1, http://links.lww.com/MLR/B352).
Measures
Smoking Status
New members who had been to at least 1 outpatient visit in the first 6 months of enrollment were assessed for smoking status through standardized screening at KPNC Medicine appointments by medical assistants. Our interest was in current smokers. In total, 90% of patients with at least 1 outpatient visit in the first 6 months of enrollment had their smoking status on record in the EHR. KPNC new members are routinely asked about their smoking status at their first KPNC visit.
Demographic Characteristics
Self-reported age, sex, and race/ethnicity were extracted from the EHR. For ease of interpretability, age was included as a categorical variable, which had no impact on the estimates for the main predictor of interest compared with other strategies for age (eg, continuous, logarithmic). Median household income was geocoded from census data using patients' addresses and was dichotomized as 1 (rmedian household salary) or 0 (> median household salary). 20, 21 
Comorbidities
We identified the most common current psychiatric disorders (depressive disorders, anxiety disorders, attention deficit hyperactivity disorders, bipolar spectrum disorders, and psychotic disorders), substance use disorders (alcohol and drug use disorders), and medical comorbidities (arthritis, hypertension, chronic pain, diabetes, asthma, chronic heart disease, and chronic obstructive pulmonary disease) in our sample based on ICD-9 diagnoses recorded by providers in the EHR during the first 6 months of KPNC enrollment.
Coverage Type
Patients were classified according to the first KPNC plan type in which they enrolled as new members in 2014: Medicaid, California exchange, or commercial (nonexchange) plans purchased by small or large employers or by individuals outside of the California exchange.
Tobacco Treatment Utilization
We coded patients as using tobacco treatment if they used medications or counseling services at any point in 2014; the timeframe for capturing utilization ranged from 6 months to 1 year (with allowable gaps). Use of tobacco-cessation medication was determined by dispensation of any FDAapproved tobacco-cessation medication [ie, nicotine replacement therapy (NRT) gum, NRT lozenge, NRT inhaler, NRT patch, NRT nasal spray, varenicline, or bupropion] from a KPNC pharmacy at any point in 2014, regardless of date of enrollment. In KPNC, a tobacco-dependence diagnosis is required for patients to receive a prescription for bupropion for tobacco dependence. Because bupropion is commonly prescribed to treat depressive disorders, we included it only if it was accompanied by a diagnosis of tobacco dependence. Data were extracted from the KPNC Pharmacy Information Management System database, which contains all data related to prescriptions dispensed at a KPNC inpatient or outpatient pharmacy.
Tobacco-cessation counseling included KPNC inperson classes or individual telephone coaching during 2014, recorded in the EHR. Health education classes are offered with clinical health educators and focus on increasing motivation to quit by providing education about nicotine addiction, discussing tobacco-cessation medications, and offering additional resources. Individual telephone coaching sessions are also available. Clinical health educators and telephone coaches can request cessation medication prescriptions from a patient's physician.
Statistical Analysis
First, we examined smoking prevalence by type of coverage among the 122,298 newly enrolled patients. We calculated the number and percentage of smokers in each subgroup and used multivariable logistic regression to assess whether coverage type, age group, race, sex, income, and comorbidities predicted the odds of being a smoker. These covariates were initially considered for inclusion in the models based on their associations with smoking, insurance type, and utilization, as detailed in the literature. 3, 10, 11, [22] [23] [24] [25] Final models were specified after running bivariate logistic models (not shown) to ensure associations between covariates and the outcomes of interest. For bivariate comparisons of multinomial outcomes, we used ordinal logistic regression for ordered outcomes (age category) and polytomous logistic regression for unordered outcomes (race). Subsequent analyses used the subsample (n = 15,936) of newly enrolled current smokers. Bivariate logistic regression assessed whether the distributions of age group, race, sex, income, comorbidities, and use of tobacco treatment were significantly different among Medicaid or exchange smokers compared with commercial plan smokers. We used the nonparametric Kruskal-Wallis test to examine differences in the median number of fills in the 3 coverage groups. Finally, coverage type was modeled as a predictor of the odds of any use of tobacco treatment, as well as the number of prescription fills for tobacco-cessation medications (1, 2-3, or 4+, not shown, adjusting for age group, race, sex, income, and comorbidities in multivariable models. Time enrolled in KPNC in 2014 was also assessed, as patients could have varying lengths of enrollment, leading to differential capture of tobacco-cessation utilization. Two-sided P-values were calculated to determine significance of measures, and significance was defined as a P < 0.05.
Bias Analyses
We conducted a bias analysis to address the potential impact of the large proportion of patients who were missing information on smoking status, as described in Appendix 2 (Supplemental Digital Content 2, http://links.lww.com/MLR/ B353). All statistical analyses were performed using SAS 9.3.
RESULTS
Correlates of Smoking
Medicaid patients were more likely to be current smokers (22%) than exchange (13%) (P < 0.0001) or commercial plan (12%) patients (P < 0.0001). Adjusting for covariates, Medicaid and exchange coverage were associated with statistically significant higher odds of smoking relative to commercial coverage [odds ratio (OR), 1.74; 95% confidence interval (CI), 1.63-1.85 and OR, 1.07; 95% CI, 1.03-1.11, respectively] ( Table 1 ). Adults aged 35 or older, with nonwhite race/ethnicity, female sex, and higher income had significantly lower odds of smoking relative to those aged 34 or younger, with white race/ethnicity, male sex, and lower income (P < 0.0001 for each). Compared with patients with no comorbidities, those with psychiatric disorders, substance use disorders, and medical comorbidities had greater odds of smoking (P < 0.0001 for each).
Characteristics of Smokers
Medicaid smokers were older, less likely to be Hispanic, Asian, Hawaiian, or Pacific Islander, or other race/ethnicity, more likely to be black or female, and had a lower income than commercial plan smokers, whereas exchange smokers were older and less likely to be black or Hispanic than commercial plan smokers (P < 0.0001 for each) ( Table 2) .
Medicaid smokers had the highest prevalence of comorbidities. More than a third (36%) had a psychiatric comorbidity diagnosis, whereas the prevalence among exchange and commercial plan smokers was 19% and 18%, respectively; depressive disorders and anxiety disorders were the most commonly diagnosed psychiatric comorbidities. Medicaid smokers were also more likely than commercial plan smokers to have a substance use disorder (12% vs. 5%, respectively) and to have Z1 medical comorbidities (59% vs. 36%, respectively) (P < 0.0001 for each). Relative to commercial smokers, exchange smokers were more likely to have an alcohol use disorder (4% vs. 3%, respectively) and to have Z1 medical comorbidities (44% vs. 36%, respectively) (P < 0.0001 for each).
Tobacco Treatment Utilization
Overall, Medicaid smokers were the most likely to use each type of tobacco treatment in 2014 (Fig. 1) . In total, 20% of Medicaid smokers versus 13% of exchange smokers and 11% of commercial plan smokers used at least 1 type of treatment (P < 0.0001 for each). Pharmacotherapy, including NRT medications, varenicline, and bupropion, accounted for most treatment. The median number of tobacco-cessation medication fills did not vary substantially by coverage type: Medicaid [median, 2.0; interquartile range (IQR), 3.0], exchange (median, 2.0; IQR, 3.0), and commercial (median, 2.0; IQR, 2.0), though the distributions of number of fills were significantly different between the 3 groups (P < 0.0001, results not shown).
Adjusting for covariates, Medicaid smokers had greater odds of using at least 1 type of tobacco treatment than commercial plan smokers (OR, 1.49; 95% CI, 1.29-1.73) ( Table 3) . Older age and female sex were significantly associated with greater odds of tobacco treatment utilization (P < 0.0001 for each), and Hispanic and Asian smokers had significantly lower odds of utilization compared with white smokers (P < 0.0001 for each). Co-occurring substance use disorders (OR, 1.61; 95% CI, 1.35-1.92), psychiatric disorders (OR, 1.80; 95% CI, 1.60-2.01), and medical comorbidities (OR, 1.38; 95% CI, 1.24-1.53) were associated with greater odds of tobacco treatment use.
Medicaid smokers had greater odds of filling multiple tobacco-cessation prescriptions than commercial smokers (OR, 1.49; 95% CI, 1.15-1.92), and exchange smokers had slightly greater (but not significant) odds (OR, 1.16; 95% CI, 0.95-1.42) (results not shown). Older smokers and those with psychiatric disorders also had significantly greater odds of filling multiple prescriptions relative to younger smokers and those without psychiatric comorbidities, whereas Hispanic smokers had 45% lower odds of filling multiple prescriptions relative to white smokers. Substance use disorders and sex were not associated with number of prescription fills.
Bias Analyses
Results of the sensitivity analyses suggested that model estimates were modestly to negligibly biased toward the null (1%-5% change in ORs); the only exception was the crude OR estimating the effect of Medicaid (vs. commercial) coverage on tobacco treatment utilization, which was estimated to be biased B30% toward the null. Using these results, we can reasonably conclude that our results are valid estimates, with some instances of underestimation and no crossover bias.
DISCUSSION
We evaluated risk factors for smoking among newly enrolled patients following the implementation of the ACA and examined the role of insurance status (ie, Medicaid, CA exchange, commercial coverage) as a predictor of tobacco treatment use (medication, counseling) among smokers post-ACA. This is one of the first studies to use an extensive EHR with population-based smoking screening to characterize smokers post-ACA in a multispecialty health care system.
As we anticipated, smoking prevalence was substantially higher among new patients with Medicaid coverage relative to new patients with commercial coverage. Smokers with Medicaid coverage were more likely to be female, less likely to be non-Hispanic white, and more likely to have low income and psychiatric, substance use, and medical comorbidities. Medicaid smokers were significantly more likely than commercial plan smokers to use tobacco treatments, including pharmacotherapy and counseling, even after adjustment for demographic and clinical characteristics. Medicaid coverage was also associated with filling a greater number of tobacco-cessation prescriptions than commercial coverage. These results are consistent with the expectation of pent-up demand among new Medicaid enrollees, and support prior research indicating that Medicaid enrollees file more claims and have greater intensity of care in their first 6 months of enrollment after the ACA. 26 Our findings suggest that implementation of the ACA may provide opportunities for reducing long-standing disparities in access to smokingcessation services for the most vulnerable segments of the population with the highest smoking rates. Conversely, smoking prevalence was low among newly insured patients with coverage through the California exchange and among those with traditional commercial plans; use of tobacco treatment was also low in these groups after adjustment for demographic characteristics and comorbidities. Given that half of individuals in the exchange in California were previously uninsured, 22 we would expect a high level of pent-up demand in this subgroup. The lack of a difference in tobacco treatment utilization in this group relative to newly insured traditional commercial members, suggests that factors other than access may be influencing health services use (eg, differences in prior experience with treatment).
Despite ACA-mandated coverage for evidence-based tobacco treatments, which includes at least 4 counseling sessions and 90 days of FDA-approved medications with no cost-sharing, there is evidence of delayed implementation of the benefit for nonexchange enrollees. For example, in 2014, 100% of KPNC patients enrolling through the California exchange and >90% of Medicaid patients received coverage for tobacco-cessation medications with no cost-sharing, whereas 80% of patients with coverage through commercial plans in 2014 still had cost-sharing for tobacco-cessation medications. KPNC eliminated cost-sharing in January 2015 for commercial plan members with ACA-compliant plans after the Departments of Health and Human Services, Labor and Treasury issued guidance about the implementation of the ACA mandate for tobacco treatments. 27 Thus, it is possible that greater utilization of tobacco-cessation medications among Medicaid versus commercial new member smokers in 2014 may be due in part to differences in cost-sharing. Conversely, despite evidence that exchange enrollees may be particularly price sensitive, 28 California exchange smokers were no more likely to use tobacco-cessation medications than commercial plan smokers. Additional research is needed to better understand underuse of tobacco treatment in this subgroup of smokers. Male smokers, younger smokers, and smokers with Asian or Hispanic race/ethnicity were less likely than female smokers, older smokers, and white smokers to use tobacco treatments, as shown in prior studies. 29, 30 Persistent challenges in engaging these patients, particularly those newly enrolled in health care, may indicate a need to develop targeted outreach and education programs. Determining the causes underlying demographic differences in use of tobacco treatments should help us understand the barriers associated with the patient (eg, low interest in treatment) and the health care system (eg, if providers are less likely to tell certain groups of patients about smoking-cessation programs and medications).
KPNC offers a unique opportunity to use data from an established EHR to conduct this study in a real-world setting that leverages external validity. However, the current study has several limitations. Our results are not directly generalizable to states with tobacco surcharges or those without Medicaid expansion, although the findings can assist policymakers and health systems in understanding early barriers to use of tobacco treatment mandated as part of health reform. Another limit of our study was that because screening for smoking occurred during routine visits, patients with no visits in the first 6 months of enrollment had no data on smoking status and thus were excluded. We addressed this issue by conducting bias analyses, and results indicated that any selection bias due to missing data was likely to bias results toward the null. In addition, our measure of over-thecounter and prescription fills for tobacco-cessation medications was limited to those dispensed at KPNC pharmacies. Although it is unlikely that patients would obtain these medications externally given that 95% of patients have KPNC drug benefits, 31 the use of smoking-cessation medications may be underestimated. Our measure of tobaccocessation counseling included KPNC in-person classes or KPNC individual telephone coaching, and may have also underestimated the true use of tobacco-cessation counseling (eg, if patients used the California tobacco quitline). Further, our data systems do not distinguish between Medicaid patients who are newly eligible due to Medicaid expansion and those who are newly enrolled but were previously eligible. Greater use of tobacco treatments in newly enrolled KPNC Medicaid smokers might reflect prior experience with Medicaid and its strong emphasis on smoking-cessation interventions. 32 Still, data from our Kaiser Division of Research Strategic Programming group show a dramatic increase in Medicaid members in 2014 and low rates of disenrollment (written communication, June 2016), suggesting that most Medicaid members in our study were newly eligible for coverage due to the ACA.
Finally, while KPNC has implemented a system-wide approach to combat smoking, including routine assessment of tobacco use status, advice to quit, referrals to cessation programs, and clinician education about the ACAs tobacco provisions, it is possible that potential differences in sites of care among the 3 cohorts of insured smokers and minor variations in provider practice patterns could partially account for the differences in tobacco-cessation medication utilization. We do not have data on clinician practices (eg, whether they advised their patient to quit, conducted brief practical counseling during the office visit). However, clinicians in KPNC are typically not aware of the type of insurance that their patients have and thus, it is highly unlikely that differential treatment by clinicians would contribute to increased treatment utilization in Medicaid patients.
CONCLUSIONS
Tobacco treatment can dramatically reduce smoking and tobacco-related diseases and lead to measurable short-term and long-term reductions in overall health expenditures, 33 yet effective treatments have been underused by low-income groups, who often lack access to appropriate treatment or cannot afford cessation medications. 3, 34 Our findings indicate low-income smokers may have improved access to health care and tobacco treatments post-ACA, possibly related to reduced barriers to utilization. Our findings can help clinicians, policymakers and health plan leadership understand which patients continue to be at risk for smoking and undertreatment for smoking post-ACA. As historically medically underserved patients are increasingly treated in accountable care organizations and other multispecialty and integrated health care systems, it will be important to develop tailored outreach, education, and enrollment efforts to and engage newly insured smokers. 35 Continued monitoring of the association of insurance coverage with use of tobacco treatments and subsequent smoking cessation will help determine whether the promise of health reform for reducing disparities in tobacco use has been met.
